Secret garden of leukemia 2025 - Relacje cyfrowe

Breaking Bad: AML edition

Agnieszka Wierzbowska

Breaking Bad: AML edition
No Time to …..Bleeding: Hemostatic Disorders in Leukemias

Maria Podolak-Dawidziak

No Time to …..Bleeding: Hemostatic Disorders in Leukemias
Genome of Secrets. Uncovering the blastic crisis of MPN and MDS

Artur Kowalik

Genome of Secrets. Uncovering the blastic crisis of MPN and MDS
Chronic myelocytic leukemia: Mission Possible – Evolving Goals and Strategies for CML Therapy

Tomasz Sacha

Chronic myelocytic leukemia: Mission Possible – Evolving Goals and Strategies for CML Therapy
The blastic phase of CML rises – How to treat refractory/resistant and blastic phase of CML?

Joanna Góra-Tybor

The blastic phase of CML rises – How to treat refractory/resistant and blastic phase of CML?
Doctor Heart: a cardiology story in CML

Sebastian Szmit

Doctor Heart: a cardiology story in CML
Shakespeare in hematology: MDS or AML, that’s the question

Krzysztof Mądry

Shakespeare in hematology: MDS or AML, that’s the question
Doubt. Transplant or not to transplant blastic phases of MPN?

Patryk Sobieralski

Doubt. Transplant or not to transplant blastic phases of MPN?
CAR-T and ALL: Avengers Endgame?

Sebastian Giebel

CAR-T and ALL: Avengers Endgame?
Bruce AL(L)mighty: Fighting Pediatric and Adolescence Leukemia

Jan Styczyński

Bruce AL(L)mighty: Fighting Pediatric and Adolescence Leukemia
Double lif(n)e of MPAL

Marta Sobas

Double lif(n)e of MPAL
Empire Strikes Back? How to treat double-refractory CLL and Richter syndrome

Krzysztof Jamroziak

Empire Strikes Back? How to treat double-refractory CLL and Richter syndrome
The outfit – Tailoring Treatment: How the presence of Unmutated IGHV and/or TP53 Mutations Change the Approach to Chronic Lymphocytic Leukemia?

Krzysztof Giannopoulos

The outfit – Tailoring Treatment: How the presence of Unmutated IGHV and/or TP53 Mutations Change the Approach to Chronic Lymphocytic Leukemia?
Edge of tomorrow? Investigating the potential of CAR T-cells and bispecific antibodies in CLL

Tomasz Wróbel

Edge of tomorrow? Investigating the potential of CAR T-cells and bispecific antibodies in CLL